Xspray Pharma Ab Stock Revenue
| XSPRAY Stock | SEK 42.10 0.10 0.24% |
XSpray Pharma AB fundamentals help investors to digest information that contributes to XSpray Pharma's financial success or failures. It also enables traders to predict the movement of XSpray Stock. The fundamental analysis module provides a way to measure XSpray Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to XSpray Pharma stock.
XSpray |
XSpray Pharma AB Company Revenue Analysis
XSpray Pharma's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, XSpray Pharma AB reported 0.0 of revenue. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The revenue for all Sweden stocks is 100.0% higher than that of the company.
XSpray Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses XSpray Pharma's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of XSpray Pharma could also be used in its relative valuation, which is a method of valuing XSpray Pharma by comparing valuation metrics of similar companies.XSpray Pharma is currently under evaluation in revenue category among its peers.
XSpray Fundamentals
| Return On Equity | -0.24 | |||
| Return On Asset | -0.14 | |||
| Operating Margin | (116.51) % | |||
| Current Valuation | 1.16 B | |||
| Shares Outstanding | 22.68 M | |||
| Shares Owned By Insiders | 47.42 % | |||
| Shares Owned By Institutions | 27.60 % | |||
| Price To Book | 2.35 X | |||
| Price To Sales | 1,206 X | |||
| Gross Profit | 656 K | |||
| EBITDA | (87.82 M) | |||
| Net Income | (96.7 M) | |||
| Cash And Equivalents | 192.85 M | |||
| Cash Per Share | 12.79 X | |||
| Total Debt | 1.19 M | |||
| Debt To Equity | 2.80 % | |||
| Current Ratio | 26.45 X | |||
| Book Value Per Share | 24.95 X | |||
| Cash Flow From Operations | (51.61 M) | |||
| Earnings Per Share | (5.18) X | |||
| Target Price | 135.0 | |||
| Number Of Employees | 26 | |||
| Beta | 0.97 | |||
| Market Capitalization | 1.45 B | |||
| Total Asset | 622.9 M | |||
| Net Asset | 622.9 M |
About XSpray Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze XSpray Pharma AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of XSpray Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of XSpray Pharma AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in XSpray Stock
XSpray Pharma financial ratios help investors to determine whether XSpray Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in XSpray with respect to the benefits of owning XSpray Pharma security.